JFJuliana Lopes Rangel Fietto

Juliana Lopes Rangel Fietto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juliana Lopes Rangel Fietto has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serological diagnosis of canine leptospirosis using a chimeric protein based on bacterial surface antigens

    by Luana de Sousa Ramos, Larissa Coelho Pereira, Elói Quintas da Silva, Victor Hugo Sousa Gonçalves, Juliana Lopes Rangel Fietto, Abelardo Silva-Junior, Yung-Fu Chang, Gustavo Costa Bressan

  • Open Access

    Bisamidine Derivatives as Candidates for Tegumentary Leishmaniasis Therapy: Phenotypic Screening in Infection of Macrophages and Mechanistic Insights with Dual RNA-seq

    by Joice Agripino, Ana C. Tahira, Luciana Ângelo de Souza, Matheus Silva e Bastos, Benjamin Sauer, Matthias Schmidt, Gustavo Costa Bressan, Raphael de Souza Vasconcellos, Wolfgang Sippl, Raymond Pierce, et al.

    Leishmania braziliensis is the primary causative agent of American tegumentary leishmaniasis (ATL), a critical parasitic tropical neglected disease. The chemotherapeutic arsenal has limited efficacy and significant toxic effects that lead to an urgent need to develop new medicines. Using the “drug repurposing” approach, histone-modifying enzyme inhibitors have been the subject of developing new drugs against neglected parasitic diseases. In this work, furamidine, a known diphenyl furan inhibitor of human Protein Arginine Methyltransferase (PRMT), along with a library of 31 developed analogues, was tested for leishmanicidal activity against L. braziliensis in the in vitro infection of macrophage assay. The most active and selective leishmanicidal analogue, BSF2 (EC50 of 0.64 μM (95% CI: 0.56–0.72), SI of 17.36), was further investigated by dual RNA-seq at 0.16 μM BSF2. The dual-transcriptome detected only 10 genes with significant differential expression (FDR ≤10%) in L. braziliensis related to ubiquitination, chromatin remodeling, and peroxisomal membrane transport pathways, following BSF2 treatment of infected macrophages. In addition, BSF2 had a significant effect (FDR ≤5%) on the expression of 577 genes in the infected macrophages, including the downregulation of TNF, IL-17, NF-κB, and Toll-like receptor pathways. This work opens new venues for developing new chemotherapy for leishmaniasis based on BSF2 or derivatives and highlights the dual transcriptome as a valuable phenotypic assay tool to investigate host–parasite interactions for antileishmanial drug discovery.


  • Open Access

    Structural Modeling of NTPDase-Substrate Complexes Preserving Catalytic Experimental Features

    by João Victor B. de Moraes, Marcelo D. Polêto, Raissa B. de Castro, Gustavo C. Bressan, Raphael de S Vasconcellos, Jean Sévigny, Juliana R. Fietto

    Members of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family play a pivotal role in hydrolyzing nucleoside triphosphates and diphosphates, modulating purinergic and pyrimidinergic signaling pathways. The NTPDases have therapeutic potential; gaining structural insights into NTPDase-substrate complexes would be valuable for optimizing these enzymes for therapeutic applications. However, such insights remain limited, posing challenges for effective optimization. Molecular docking often fails to capture experimentally characterized substrate conformations, leading to biologically irrelevant models. To address this, we developed a computational strategy that preserves experimentally observed substrate features while leveraging the active site's conservation across NTPDases. Our method identifies a canonical linear-like substrate conformation encompassing the phosphate tail and nucleobase ring conserved across experimental NTPDase structures. This approach enabled the modeling of Homo sapiens (Hs) NTPDases (HsNTPDase1-8) complexed with ATP, ADP, GTP, GDP, UTP, and UDP, accurately positioning metal ion cofactor and catalytic water molecules. The resulting models offer a reliable framework for studying enzyme-substrate interactions, paving the way for rational enzyme engineering and therapeutic exploration.


  • Open Access

    ENTPDase inhibitors: therapeutic potential in infectious, inflammatory, and neuroinflammatory diseases

    by Isadora Cunha Ribeiro, Amanda Laviola de Andrade, Vitória de Almeida Rodrigues, Markson Suarez Lacôrte Lima, Juliana Lopes Rangel Fietto

    Ectonucleoside triphosphate diphosphohydrolases (ENTPDases), members of the cluster of differentiation 39 (CD39) family, are key regulators of purinergic signaling through the hydrolysis of tri and diphosphate nucleotides. These enzymes are expressed on the cell surface, extracellular environment, or within intracellular organelles such as the Golgi apparatus. ENTPDases play critical roles in modulating immune responses, inflammation, and neuroinflammation by controlling extracellular nucleotide availability in mammals. Moreover, they contribute to adenosine-mediated signaling in cooperation with 5’-nucleotidases (CD73). Pathogenic microorganisms also express ENTPDases, manipulating host purinergic signaling, suppressing adenosine triphosphate (ATP)-driven inflammation, and promoting immune evasion via increased adenosine production. Pathogenic parasites also express ENTPDases, manipulating host purinergic signaling, suppressing ATP-driven inflammation, and promoting immune evasion via increased adenosine production. Given their involvement in infection and inflammatory diseases, ENTPDases have emerged as promising pharmacological targets. This review comprehensively analyzes the ENTPDases from mammals and pathogenic parasites, emphasizing their role in purinergic signaling and their potential as therapeutic targets. While ENTPDase inhibitors hold promise for modulating inflammation and infection, their clinical translation faces challenges, including selectivity, off-target effects, and systemic alterations in purinergic homeostasis. Addressing these concerns through targeted drug delivery, allosteric modulation, and improved inhibitor specificity is crucial for therapeutic advancements.


  • Open Access

    Histone Deacetylase Inhibitors Show a Potential Leishmanicidal Effect against Leishmania braziliensis in a Mouse Infection Model and Lead to Less Toxicity than Glucantime

    by Luciana Ângelo de Souza, Lethícia Kelly Ramos Andrade, Joice de Melo Agripino, Victor Hugo Ferraz da Silva, Sabrina de Oliveira Emerick, Adriana Carneiro da Silva, Larissa Coelho Pereira, Graziela Domingues de Almeida Lima, Ingrid Rabite Garcia, Anna Cláudia Alves Souza, et al.

    Leishmania braziliensis is the primary cause of cutaneous leishmaniasis (CL) in the New World. Current treatments have significant limitations, including severe side effects and parasite resistance. Histone deacetylases (HDAC) are critical regulators of chromatin structure and represent potential drug targets for leishmaniasis. This study evaluated three HDAC inhibitors (HDACi), TH60, TH74, and TH85, in BALB/c mice infected with L. braziliensis, comparing their efficacy to the standard treatment, glucantime. Two doses were tested, and lesion size, parasite load, kidney and liver enzyme levels, and histopathological analyses were carried out. HDACi effectively reduced lesion size and parasite presence, with lower toxicity and fewer organ alterations than glucantime. Among the tested compounds, TH60 was the best-tested HDACi. These findings highlight the potential application of the tested HDACi as leishmanicidal agents against L. braziliensis, positioning them as promising candidates for developing new drugs targeting cutaneous leishmaniasis.


  • Open Access

    Synthesis and Antileishmanial Evaluation of N-Phenyl-2-phenoxyacetamides Derived from Carvacrol

    by Rayane Luiza de Carvalho, Alícia da Conceição Terbutino da Silva, Bianca Muniz Lacerda Ventura, Sara Andrade Machado Godoy, Olívia Géraldine Audrey Avome Nguema, Juliana Lopes Rangel Fietto, Christiane Mariotini-Moura, Michelle Dias de Oliveira Teixeira, Raphael de Souza Vasconcellos, Angel Amado Recio Despaigne, et al.

    Leishmaniasis, caused by protozoa of the genus Leishmania and transmitted by sandflies, remains prevalent in underdeveloped countries. The disease manifests in three clinical forms: cutaneous, mucocutaneous, and visceral, the latter being fatal without adequate treatment. Current therapies, including pentavalent antimonials, have important limitations, such as high toxicity and reduced efficacy. This study investigates synthetic compounds derived from carvacrol as potential therapeutic alternatives. Carvacrol serves as a precursor for the synthesis of carvacroxyacetic acid, a key intermediate in producing N-phenyl-2-phenoxyacetamides. Ten novel molecules were synthesized with yields ranging from 11% to 60%. All synthesized compounds were characterized using mass spectrometry, 1H NMR and 13C NMR. Additionally, the structure of compound 9 (C18H20FNO2) was confirmed by X-ray crystallography. Cytotoxicity assays with macrophages and Vero cells revealed that all ten N-phenyl-2-phenoxyacetamides exhibited low or no toxicity at the tested concentrations. Compounds 5 and 7 demonstrated significant antileishmanial activity against Leishmania braziliensis, outperforming both the untreated control and the precursor carvacroxyacetic acid (CA). Furthermore, their efficacy against the parasite exceeded for the activity of pure carvacrol reported in the literature. These findings highlight the significant potential of these compounds and emphasize the importance of further studies to elucidate their mechanisms of action and explore broader therapeutic applications.


  • Development and preliminary study of the rLiNTPDase2 rapid test: A lateral flow immunochromatographic assay for Canine Visceral Leishmaniasis

    by Raissa Barbosa de Castro, Luma Salgado Leopoldino, João Victor Badaró de Moraes, Gustavo Costa Bressan, Raphael de Souza Vasconcellos, Evandro Silva Favarato, Fabiana Azevedo Voorwald, Juliana Lopes Rangel Fietto

  • Heterologous expression and biochemical characterization of the recombinant nucleoside triphosphate diphosphohydrolase 2 (LbNTPDase2) from Leishmania (Viannia) braziliensis

    by Nancy da Rocha Torres Pavione, João Victor Badaró de Moraes, Isadora Cunha Ribeiro, Raissa Barbosa de Castro, Walmir da Silva, Anna Cláudia Alves de Souza, Victor Hugo Ferraz da Silva, Raphael de Souza Vasconcellos, Gustavo da Costa Bressan, Juliana Lopes Rangel Fietto

    Leishmania braziliensis is a pathogenic protozoan parasite that causes American Tegumentary Leishmaniasis (ATL), an important tropical neglected disease. ENTPDases are nucleotidases that hydrolyze intracellular and/or extracellular nucleotides. ENTPDases are known as regulators of purinergic signalling induced by extracellular nucleotides. Leishmania species have two isoforms of ENTPDase, and, particularly, ENTPDase2 seems to be involved in infectivity and virulence. In this study, we conducted the heterologous expression and biochemical characterization of the recombinant ENTPDase2 of L. braziliensis (rLbNTPDase2). Our results show that this enzyme is a canonical ENTPDase with apyrase activity, capable of hydrolysing triphosphate and diphosphate nucleotides, and it is dependent on divalent cations (calcium or magnesium). Substrate specificity was characterized as UDP>GDP>ADP>GTP>ATP=UTP. The enzyme showed optimal activity at a neutral to basic pH and was partially inhibited by suramin and DIDS. Furthermore, the low apparent Km for ADP suggests that the enzyme may play a role in adenosine-mediated signalling. The biochemical characterization of this enzyme can open new avenues for using LbNTPDase2 as a drug target. Graphical abstract


  • Synthesis of new non-natural l-glycosidic flavonoid derivatives and their evaluation as inhibitors of Trypanosoma cruzi ecto-nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1)

    by Isadora Cunha Ribeiro, João Victor Badaró de Moraes, Christiane Mariotini-Moura, Marcelo Depolo Polêto, Nancy da Rocha Torres Pavione, Raissa Barbosa de Castro, Izabel Luzia Miranda, Suélen Karine Sartori, Kryssia Lohayne Santos Alves, Gustavo Costa Bressan, et al.

    Trypanosoma cruzi is the pathogen of Chagas disease, a neglected tropical disease that affects more than 6 million people worldwide. There are no vaccines to prevent infection, and the therapeutic arsenal is very minimal and toxic. The unique E-NTPDase of T. cruzi (TcNTPDase1) plays essential roles in adhesion and infection and is a virulence factor. Quercetin is a flavonoid with antimicrobial, antiviral, and antitumor activities. Its potential as a partial inhibitor of NTPDases has also been demonstrated. In this work, we synthesized the non-natural l-glycoside derivatives of quercetin and evaluated them as inhibitors of recombinant TcNTPDase1 (rTcNTPDase1). These compounds, and quercetin and miquelianin, a natural quercetin derivative, were also tested. Compound 16 showed the most significant inhibitory effect (94%). Quercetin, miquelianin, and compound 14 showed inhibition close to 50%. We thoroughly investigated the inhibitory effect of 16. Our data suggested a competitive inhibition with a Ki of 8.39 μM (± 0.90). To better understand the interaction of compound 16 and rTcNTPDase1, we performed molecular dynamics simulations of the enzyme and docking analyses with the compounds. Our predictions show that compound 16 binds to the enzyme’s catalytic site and interacts with important residues for NTPDase activity. As an inhibitor of a critical T. cruzi enzyme, (16) could be helpful as a starting point in the developing of a future treatment for Chagas disease. Furthermore, the discovery of (16) as an inhibitor of TcNTPDase1 may open new avenues in the study and development of new inhibitors of E-NTPDases.


  • Leishmania infantum NTPDase1 and NTPDase2 play an important role in infection and nitric oxide production in macrophages

    by Walmir da Silva, Isadora Cunha Ribeiro, Joice de Melo Agripino, Victor Hugo Ferraz da Silva, Luciana Ângelo de Souza, Tatiana Aparecida Oliveira, Gustavo Costa Bressan, Raphael de Souza Vasconcellos, Carole Dumas, Julie Pelletier, et al.